MRK  Merck & Company Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

174.8B

Vuru Grade

47.84/100

Current Price

$60.61
+0.30 (+0.50%)

Growth Price

$46.98
Overvalued by 22.49%

Stability Price

$23.38
Overvalued by 61.43%

Company Metrics

  • 31.78 P/E
  • 3.99 P/S
  • 3.62 P/B
  • 1.898 EPS
  • 10.80% Cash ROIC
  • 0.98 Cash Ratio
  • 1.76 / 2.92% Dividend
  • 8.22M Avg. Vol.
  • 2.88B Shares
  • 174.8B Market Cap.

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Sun Pharma, Merck & Co Inc enter into pact for Tildrakizumab
Economic Times - Sep 17, 2014
"Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post ...
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for ... - MarketWatch
Merck licenses experimental psoriasis drug to India's Sun Pharma - Reuters
3 Reasons Merck & Co., Inc.'s Stock Could Fall
Motley Fool - Aug 28, 2014
If you were lucky enough to time your purchase of Merck (NYSE: MRK ) during the heights of the Great Recession, your investment has probably seen a return of 100% or greater.
Merck Reports Progress In Type-2 Diabetes Drug Trials
Bidness ETC - Sep 18, 2014
Merck & Co., Inc. (MRK) announced yesterday, early results from its Phase III developmental program, which evaluated the efficacy and safety of omarigliptin for the treatment of type-2 diabetes.
Is it Time to Buy Merck & Co., Inc.'s Stock?
Motley Fool - Sep 4, 2014
Investors in pharmaceutical giant Merck (NYSE: MRK ) have to be liking what they've witnessed in recent years as Merck's stock has vaulted to its highest levels since prior to the Great Recession. However, back Merck's chart out to a 15-year view and ...
Merck & Co., Inc. Wins First Stage of the PD-1 Race
Motley Fool - Sep 5, 2014
Merck (NYSE: MRK ) has won the race to get the first immunotherapy drug that blocks the PD-1 pathway on the U.S. market. Today, the FDA approved pembrolizumab, which will go by the brand name Keytruda, for patients with advanced or unresectable ...
Merck Beats Bristol-Myers In Breakthrough Cancer Drug Race - Bidness ETC
FDA OKs Merck melanoma drug, 1st in its class - CNBC
Sun Pharma, Merck & Co Inc ink pact for Tildrakizumab
Moneycontrol.com - Sep 17, 2014
Pharma major Sun Pharmaceutical Industries today entered into a licensing agreement with Merck & Co Inc for investigational therapeutic antibody candidate, tildrakizumab to be used for treatment of plaque psoriasis.
Merck Announces Positive Phase III Results For Odanacatib; Drug's Safety ...
Bidness ETC - Sep 16, 2014
Merck & Co., Inc. (MRK) announced yesterday, positive results from Phase III trials of its drug odanacatib, used to treat osteoporosis in postmenopausal women.
Stock Update: Merck & Co Inc (NYSE:MRK) – Merck Announces Data from ... - Jutia Group
Merck Says Odanacatib Meets Primary Endpoints Phase 3 Fracture Outcomes ... - NASDAQ
Bristol-Myers Squibb Co (BMY) Sues Merck & Co., Inc. (MRK) Over Cancer Drug ...
Insider Monkey (blog) - Sep 9, 2014
Bristol-Myers Squibb Co (NYSE:BMY) along with Ono Pharmaceutical launched a lawsuit against Merck & Co., Inc. (NYSE:MRK) last Thursday, claiming that the company's new cancer drug Keytruba (which was approved by the FDA the same day) violates ...
Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog - NASDAQ
Merck & Co. Inc. (MRK) Tops DJIA Gainers for September 3
Equities.com - Sep 3, 2014
The Dow closed at 17,078.30 on Wednesday, which is a 0.06% move from yesterday's close. Merck & Co. Inc. led all gainers with a 1.15% jump.
Merck, Bristol-Myers Continue Battle Over Cancer Immunotherapy Treatment
Bidness ETC - Sep 8, 2014
Merck & Co., Inc.'s (MRK) anti-melanoma immunotherapy drug, Keytruda, recently got accelerated approval from the US Food and Drug Administration (FDA).
Merck & Co., Inc. (NYSE:MRK) Dragged To Court On Immunotherapy Patent Issue - WallStreetPR
FDA OKs Merck drug, 1st in new cancer drug class - Casper Star-Tribune Online